Index -
P/E -
EPS (ttm) -2.67
Insider Own 15.88%
Shs Outstand 60.47M
Perf Week 1.02%
Market Cap 473.34M
Forward P/E -
EPS next Y -1.88
Insider Trans 0.00%
Shs Float 57.71M
Perf Month -16.06%
Income -132.49M
PEG -
EPS next Q -0.36
Inst Own 71.91%
Short Float 15.85%
Perf Quarter 22.34%
Sales 20.76M
P/S 22.80
EPS this Y 30.76%
Inst Trans -1.55%
Short Ratio 3.43
Perf Half Y 268.98%
Book/sh 4.07
P/B 1.70
EPS next Y -1.95%
ROA -32.82%
Short Interest 9.15M
Perf Year 109.73%
Cash/sh 3.70
P/C 1.87
EPS next 5Y 22.30%
ROE -49.50%
52W Range 1.06 - 11.88
Perf YTD 22.12%
Dividend Est. -
P/FCF -
EPS past 5Y -36.05%
ROI -42.48%
52W High -41.92%
Beta 3.19
Dividend TTM -
Quick Ratio 6.34
Sales past 5Y 7.65%
Gross Margin 62.72%
52W Low 550.94%
ATR (14) 0.51
Dividend Ex-Date -
Current Ratio 6.34
EPS Y/Y TTM -1.78%
Oper. Margin -669.84%
RSI (14) 36.88
Volatility 5.27% 5.79%
Employees 145
Debt/Eq 0.29
Sales Y/Y TTM -33.25%
Profit Margin -638.34%
Recom 1.67
Target Price 17.22
Option/Short Yes / Yes
LT Debt/Eq 0.27
EPS Q/Q 10.64%
Payout -
Rel Volume 0.34
Prev Close 6.86
Sales Surprise 1.92%
EPS Surprise 1.00%
Sales Q/Q 14.26%
Earnings Feb 22 BMO
Avg Volume 2.66M
Price 6.90
SMA20 -8.54%
SMA50 -18.88%
SMA200 50.45%
Trades
Volume 911,554
Change 0.58%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Upgrade
JP Morgan
Underweight → Neutral
$6
Dec-13-23 Upgrade
Stifel
Hold → Buy
$2 → $12
Feb-24-23 Upgrade
Credit Suisse
Underperform → Neutral
$12 → $10
Feb-24-23 Downgrade
JP Morgan
Neutral → Underweight
$15 → $5
Nov-04-22 Downgrade
JP Morgan
Overweight → Neutral
$22 → $15
Oct-11-22 Initiated
Morgan Stanley
Underweight
$6
Apr-28-22 Initiated
Credit Suisse
Underperform
$10
Apr-11-22 Downgrade
BofA Securities
Buy → Neutral
$46 → $15
Mar-10-22 Initiated
JP Morgan
Overweight
$43
Feb-11-22 Resumed
BMO Capital Markets
Outperform
$57
Feb-10-22 Initiated
Wells Fargo
Equal Weight
$25
Nov-23-21 Initiated
BofA Securities
Buy
$54
Oct-14-21 Initiated
SVB Leerink
Mkt Perform
$20
Sep-30-21 Initiated
Stifel
Hold
$45
Jun-04-21 Initiated
H.C. Wainwright
Buy
$63
Mar-31-21 Initiated
BMO Capital Markets
Outperform
$55
Oct-28-20 Initiated
UBS
Buy
$44
Oct-27-20 Initiated
Jefferies
Buy
$34
Oct-27-20 Initiated
BMO Capital Markets
Outperform
$33
Show Previous Ratings
Apr-09-24 07:00AM
Apr-08-24 08:00AM
Mar-28-24 04:36AM
Mar-05-24 04:30PM
Mar-04-24 07:00AM
08:15AM
Loading…
Feb-22-24 08:15AM
07:36AM
07:00AM
Feb-15-24 10:19AM
10:00AM
Jan-11-24 11:44AM
Jan-09-24 06:20PM
04:01PM
Jan-04-24 04:01PM
07:00AM
11:10AM
Loading…
Jan-03-24 11:10AM
Jan-01-24 09:55AM
Dec-27-23 07:35PM
Dec-15-23 09:55AM
Dec-13-23 12:39PM
Dec-12-23 04:01PM
10:13AM
07:00AM
Nov-28-23 07:00AM
Nov-20-23 07:00AM
Nov-13-23 09:55AM
Nov-01-23 11:03AM
(FierceBiotech.com) -11.41%
09:40AM
07:00AM
Oct-11-23 07:00AM
04:01PM
Loading…
Sep-05-23 04:01PM
Aug-28-23 06:30PM
Aug-08-23 08:40AM
07:00AM
Aug-04-23 06:58AM
Jul-17-23 07:00AM
Jul-05-23 07:00AM
Jun-20-23 07:00AM
May-30-23 07:00AM
May-14-23 08:06AM
May-04-23 08:15AM
07:00AM
Apr-19-23 07:00AM
Apr-11-23 09:35AM
Mar-23-23 07:39AM
Feb-24-23 05:38AM
(Simply Wall St.) -11.46%
Feb-23-23 08:35AM
07:00AM
Feb-08-23 07:00AM
Jan-30-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 06:15PM
Jan-04-23 09:40AM
Jan-03-23 07:00AM
Nov-13-22 07:13AM
Nov-08-22 09:55AM
Nov-03-22 08:25AM
07:00AM
Nov-02-22 10:01AM
Oct-03-22 09:02AM
Sep-29-22 07:00AM
Sep-26-22 07:00AM
Sep-06-22 08:22AM
Aug-10-22 06:05AM
Aug-07-22 08:21AM
Aug-04-22 09:15AM
08:00AM
Aug-02-22 08:00AM
May-16-22 08:00AM
May-05-22 09:15AM
08:00AM
Apr-08-22 02:15PM
01:00PM
10:05AM
Mar-17-22 11:44AM
Mar-16-22 04:05PM
Mar-09-22 08:00AM
Mar-08-22 04:30PM
Feb-24-22 07:00AM
Feb-07-22 04:45AM
Jan-12-22 11:09AM
Jan-10-22 07:00AM
Jan-03-22 07:00AM
Dec-29-21 12:00PM
Dec-17-21 08:00AM
Dec-01-21 07:28AM
Nov-22-21 12:00PM
Nov-10-21 04:01PM
08:34AM
Oct-26-21 10:41AM
Oct-09-21 09:14AM
Sep-17-21 10:27AM
Aug-11-21 04:02PM
04:01PM
Aug-10-21 01:31AM
Jul-21-21 04:24AM
Jul-19-21 01:44PM
(Investor's Business Daily)
Jun-21-21 04:01PM
08:00AM
Jun-16-21 07:51PM
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Index RUT
P/E -
EPS (ttm) -3.97
Insider Own 5.92%
Shs Outstand 94.67M
Perf Week 14.30%
Market Cap 86.40M
Forward P/E 181.90
EPS next Y 0.01
Insider Trans -0.18%
Shs Float 89.37M
Perf Month -12.55%
Income -331.94M
PEG -
EPS next Q -0.03
Inst Own 49.33%
Short Float 11.61%
Perf Quarter 7.56%
Sales 152.07M
P/S 0.57
EPS this Y -121.82%
Inst Trans 11.54%
Short Ratio 11.40
Perf Half Y -60.11%
Book/sh 1.46
P/B 0.62
EPS next Y 104.17%
ROA -94.80%
Short Interest 10.38M
Perf Year -85.26%
Cash/sh 0.77
P/C 1.18
EPS next 5Y 25.00%
ROE -182.52%
52W Range 0.75 - 8.01
Perf YTD -15.00%
Dividend Est. -
P/FCF 1.76
EPS past 5Y -
ROI -186.50%
52W High -88.65%
Beta 1.01
Dividend TTM -
Quick Ratio 1.43
Sales past 5Y -7.51%
Gross Margin 64.04%
52W Low 21.11%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 1.83
EPS Y/Y TTM -272.27%
Oper. Margin 10.79%
RSI (14) 52.56
Volatility 7.96% 6.45%
Employees 53
Debt/Eq 0.30
Sales Y/Y TTM -2.66%
Profit Margin -218.28%
Recom 1.00
Target Price 3.00
Option/Short Yes / Yes
LT Debt/Eq 0.29
EPS Q/Q -145.92%
Payout -
Rel Volume 1.21
Prev Close 0.87
Sales Surprise -3.39%
EPS Surprise -
Sales Q/Q -34.49%
Earnings Mar 11 AMC
Avg Volume 909.99K
Price 0.91
SMA20 1.45%
SMA50 0.22%
SMA200 -54.79%
Trades
Volume 1,100,433
Change 5.11%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-07-22 Initiated
Lake Street
Buy
$7
Nov-30-18 Downgrade
Mizuho
Buy → Neutral
Apr-03-24 08:00AM
Apr-01-24 09:00AM
Mar-12-24 11:11AM
08:31AM
05:49AM
(Thomson Reuters StreetEvents)
04:26PM
Loading…
Mar-11-24 04:26PM
(Associated Press Finance)
04:01PM
Mar-04-24 05:07PM
Feb-29-24 04:05PM
Feb-28-24 10:15AM
Feb-26-24 07:57PM
Feb-23-24 11:30AM
05:45AM
Feb-22-24 12:35PM
Feb-19-24 12:39PM
12:41PM
Loading…
Feb-16-24 12:41PM
11:28AM
Feb-13-24 05:45AM
Feb-12-24 10:30AM
Feb-09-24 02:51PM
Feb-05-24 03:56PM
10:24AM
10:08AM
Feb-02-24 12:32PM
12:19PM
Jan-29-24 12:30PM
Jan-26-24 09:15AM
Jan-24-24 06:54PM
10:15AM
Jan-22-24 03:42PM
09:36AM
Loading…
Jan-19-24 09:36AM
Jan-17-24 10:15AM
09:35AM
Jan-15-24 03:29PM
Jan-10-24 10:45AM
Jan-08-24 12:14PM
Jan-05-24 06:56PM
Jan-04-24 09:46AM
Jan-03-24 08:59AM
Dec-25-23 02:06PM
Nov-14-23 08:00AM
Nov-10-23 01:11PM
Nov-09-23 08:49AM
(Thomson Reuters StreetEvents) -43.19%
Nov-08-23 06:46PM
04:30PM
(Associated Press Finance)
04:01PM
Nov-02-23 12:06PM
Oct-06-23 04:30PM
Sep-22-23 08:38AM
Sep-14-23 01:12PM
Aug-28-23 06:30PM
Aug-25-23 04:05PM
Aug-23-23 08:48AM
Aug-08-23 04:45PM
09:15AM
Aug-06-23 08:05AM
07:14AM
Aug-03-23 04:29PM
(Associated Press Finance)
04:04PM
Jul-31-23 07:27PM
Jul-27-23 04:01PM
Jul-24-23 08:30AM
Jul-19-23 07:38AM
Jul-07-23 09:16AM
Jun-26-23 07:00AM
Jun-16-23 06:30AM
May-26-23 12:06PM
May-10-23 06:12AM
01:34AM
(Thomson Reuters StreetEvents)
May-09-23 07:28AM
07:15AM
06:02AM
May-05-23 08:00AM
May-04-23 10:54AM
06:10AM
Apr-27-23 09:00AM
Apr-25-23 01:03PM
06:00AM
Apr-24-23 09:00AM
09:00AM
Apr-17-23 06:43AM
Apr-10-23 09:00AM
Apr-07-23 04:00PM
Mar-29-23 10:13AM
Mar-27-23 09:00AM
Mar-14-23 09:00AM
Mar-10-23 02:37AM
Mar-09-23 12:19PM
(Thomson Reuters StreetEvents) +11.74%
Mar-08-23 11:43PM
(Thomson Reuters StreetEvents)
04:01PM
Mar-06-23 09:00AM
06:00AM
Mar-03-23 09:00AM
Mar-02-23 08:34AM
Mar-01-23 12:41PM
Feb-23-23 07:14AM
Feb-21-23 07:00AM
Feb-20-23 09:00AM
Feb-16-23 08:00AM
Feb-14-23 09:30AM
Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Tyree James L Director Mar 14 '24 Sale 1.12 10,251 11,463 188,251 Mar 15 08:01 PM Schlessinger Sam SVP, General Counsel Feb 21 '24 Option Exercise 0.00 17,151 0 109,384 Feb 23 05:32 PM Patel Ajay SVP and CFO Feb 21 '24 Option Exercise 0.00 17,151 0 141,760 Feb 23 05:30 PM Schwichtenberg Paul SVP, CCO Feb 21 '24 Option Exercise 0.00 17,151 0 112,430 Feb 23 05:31 PM Schlessinger Sam SVP, General Counsel Feb 11 '24 Option Exercise 0.00 18,939 0 98,785 Feb 13 07:02 PM Patel Ajay SVP and CFO Feb 11 '24 Option Exercise 0.00 47,348 0 140,991 Feb 13 07:00 PM Schwichtenberg Paul See Remarks Feb 11 '24 Option Exercise 0.00 47,348 0 111,661 Feb 13 07:01 PM Schlessinger Sam SVP, General Counsel Oct 01 '23 Option Exercise 0.00 19,404 0 88,442 Oct 03 07:27 PM Peisert Daniel A. President & CEO Sep 12 '23 Sale 2.97 31,121 92,432 324,939 Sep 13 08:15 PM Peisert Daniel A. President & CEO Sep 11 '23 Sale 3.04 127,281 386,972 356,060 Sep 13 08:15 PM Schwichtenberg Paul SVP and CFO Sep 11 '23 Sale 3.07 104,980 322,593 64,313 Sep 13 08:16 PM Patel Ajay SVP and CAO Sep 11 '23 Sale 3.04 64,313 195,794 93,643 Sep 13 08:17 PM Schlessinger Sam SVP, General Counsel Sep 11 '23 Sale 3.04 45,236 137,441 69,038 Sep 13 08:18 PM MCKEE WILLIAM Director Aug 14 '23 Sale 3.14 22,000 69,045 238,780 Aug 15 06:00 PM Schlessinger Sam SVP, General Counsel Aug 05 '23 Option Exercise 0.00 7,135 0 117,434 Aug 08 07:00 PM Mason Heather L Director May 19 '23 Sale 7.30 89,286 652,011 187,650 May 22 08:00 PM Patel Ajay SVP and CAO May 12 '23 Option Exercise 0.00 238,017 0 314,819 May 15 08:58 PM Schlessinger Sam SVP, General Counsel May 12 '23 Option Exercise 0.00 238,017 0 267,162 May 15 08:58 PM Peisert Daniel A. President and CEO May 12 '23 Option Exercise 0.00 552,067 0 797,066 May 15 08:57 PM Schwichtenberg Paul SVP and CFO May 12 '23 Option Exercise 0.00 238,017 0 326,156 May 15 08:58 PM Tyree James L Director May 05 '23 Sale 6.00 43,143 258,767 167,308 May 05 09:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite